雷公藤多苷治疗紫癜性肾炎34例疗效观察被引量：10

下载PDF

导出

摘要目的评价雷公藤多苷(TG)治疗紫癜性肾炎(HSPN)的疗效及其近期不良反应,为临床合理用药提供指导。方法选取2007年2月至2010年3月我院儿科门诊及住院初发HSPN患儿64例,随机分为治疗组和对照组,其中治疗组34例,在口服泼尼松基础上口服雷公藤;对照组30例,口服泼尼松治疗。结果治疗组显效12例(35.3%),有效17例(50.0%),无效5例(14.7%),总有效率为85.3%;对照组显效9例(30.0%),有效13例(43.3%),无效8例(26.7%),总有效率为73.3%,治疗组总有效率明显高于对照组,两组比较差异有统计学意义(P<0.05)。结论雷公藤多苷(TG)结合泼尼松治疗紫癜性肾炎(HSPN)的疗效优于单用泼尼松治疗。

作者庞福明

机构地区博白县人民医院

出处《海南医学》 CAS 2011年第10期84-85,共2页 Hainan Medical Journal

关键词雷公藤多苷紫癜性肾炎疗效

分类号 R692.34 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献7

1范国华,高瑞洁,董春萍.不典型小儿过敏性紫癜8例误诊分析[J].新医学,2005,36(12):710-711. 被引量：4
2Rostoker C. Schonlein-Henochpura pura in children and adults: diagnosis, pathophysiology and inanagement [J]. Biol Drugs, 2001, 15 (2): 99-138.
3Davin JC, Weening JJ. Henoch-schonlein purpura nephritis:anupdatt [J]. Eur J pedicctr, 2001, 160(12): 689-695.
4中华医学会儿科学分会肾脏病学组,姚勇,杨霁云,陈述枚,丁洁.小儿肾小球疾病的临床分类、诊断及治疗[J].中华儿科杂志,2001,39(12):746-749. 被引量：1529
5孙良忠,Ibrini Juma,Parker Emma,陈述枚,Johnson Timothy S.,El Nahas A. Meguid.白蛋白刺激肾小管上皮细胞表达基质金属蛋白酶2和9[J].中华肾脏病杂志,2007,23(8):519-523. 被引量：9
6杨华彬,易著文.小儿过敏性紫癜性肾炎的药物治疗进展[J].实用药物与临床,2005,8(1):12-14. 被引量：47
7张西强.雷公藤多甙在自身免疫性疾病中的应用[J].山东医学高等专科学校学报,2007,29(5):367-370. 被引量：10

二级参考文献34

1刘伏友.蛋白尿致肾小管间质纤维化的机制及防治[J].中华肾脏病杂志,2006,22(5):258-260. 被引量：39
2Flynn JT, Somyer WE, Bunchaman TE, et al. Treatment of Henoch-Schonlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide[J]. Am J Nephrol, 2001,21(2): 128-133.
3Niaudet P, Habib R. Methylprednisone pulse therapy in the treatment of severe forms of Henoch-Schonlein purpura nephritis [J]. Pediatr Nephrol, 1998, 12(3):238-243.
4Kawasaki Y, Suzuki J, Nozawa R, et al. Efficacy of methyprednisolone and urokinase pulse therapy for severe Henoch-Schonlein nephritis. Pediatrics[J]. 2003.111(4Pt1): 785-789.
5Eddy AA. Proteinuria and interstitial injury. Nephrol Dial Transplant, 2004, 19: 277-281.
6Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol, 2001, 159: 1465-1475.
7Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol, 2004, 15:1-12.
8Imai E, Nakajima H, Kaimori JY. Albumin turns on a vicious spiral of oxidative stress in renal proximal tubules. Kidney Int, 2004, 66: 2085-2087.
9Lelongt B, Legallicier B, Piedagnel R, et al. Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases? Curr Opin Nephrol Hypertens, 2001, 10: 7-12.
10Klein G, Vellenga E, Fraaije MW, et al.The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol, 2004, 50: 87-100.